{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"13"},{"groupId":"OG001","value":"6"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"13"},{"groupId":"OG001","value":"6"}],"units":"Participants"}],"description":"Histologic downgrade by at least one grade of dysplasia (e.g Severe to Moderate).","groups":[{"description":"Patients receive cetuximab IV over 1-2 hours on days 1, 8, 15, 22, 29, 36, 43, and 50 in the absence of disease progression or unacceptable toxicity.\n\ncetuximab: given IV","id":"OG000","title":"Arm I (Treatment)"},{"description":"Patients receive regular follow-up care","id":"OG001","title":"Arm II (Control)"}],"paramType":"COUNT_OF_PARTICIPANTS","reportingStatus":"POSTED","timeFrame":"8 weeks","title":"Number of Participants With Objective Response Based on Histologic Grade","type":"PRIMARY","unitOfMeasure":"Participants"}